

# News

## Portuguese Association of Urology

The Congress of the Portuguese Association of Urology will be held in Funchal, Madeira Island, 12–15 June 1991. The main topics of the meeting are surgical vs. non-surgical treatment of benign prostatic hypertrophy, prosthesis and cost-benefit ratio in urology. For further details contact: Dr Manuel Mendes Silva, Rua Consiglieri Pedroso 123, 2745 Queluz, Portugal. Tel (351) 1 4354044, fax (351) 1 4355334.

## Brachytherapy Meeting

The annual Brachytherapy Meeting, organised by Groupe Européen de Curiethérapie (GEC) and the European Society for Therapeutic Radiology and Oncology (ESTRO), will take place in Baden Baden, Germany, 15–17 May 1991. Full details of the main meeting and the teaching course can be obtained from the ESTRO Secretariat, Department of Radiotherapy, U H St Rafael, Capucijnenvoer 33, 3000 Leuven, Belgium. Tel (32) 16 212 213, fax (32) 16 212 228.

## European Congress of Radiology

The European Congress of Radiology will take place in Vienna, Austria, 15–20 September 1991. Further details can be obtained from the administrative and scientific secretariat, ECR '91, The Vienna Academy of Postgraduate Medical Education and Research, Alserstrasse 4, A-1090 Vienna, Austria. Tel (43) 1 42 13 83-0 or 1 42 71 65, fax (43) 1 42 13 83-23.

## American Association for Cancer Research

The 82nd annual meeting of the American Association for Cancer Research will take place on 15–18 May 1991 in Houston, Texas, USA. Full details can be obtained from the American Association for Cancer Research, Public Ledger Building, Suite 816, 6th and Chestnut Streets, Philadelphia, PA 19106, USA. Tel (1) 215 440 9300, fax (1) 215 440 9313.

## ESMO Fellowships for Medical Oncology

The Fellowship and Award Committee of the European Society for Medical Oncology (ESMO) fosters a fellowship programme. The aim of this programme is to provide scholarships to young medical oncologists for 1 or 2 years of preclinical training in an outstanding European laboratory. These fellowships will be sponsored by a number of pharmaceutical firms. Several firms have already welcomed the idea of the ESMO fellowship programme. Boehringer Ingelheim, Hoffmann–La Roche, Amgen, Glaxo and Sterling were the first companies to sponsor the programme.

Candidates should meet the following requirements. The age limit is 35, the applicant must have trained for at least 3 years, and have clinical experience in medical oncology. The applicant should be, or commit himself or herself to becoming an ESMO member. His or her origin institute has to be an ESMO member and the host has to be or become an ESMO member.

Candidates are invited to submit applications to the chairman of the Fellowship Committee which will select the future fellowship recipients. Application files should include: (1) curriculum vitae and career goals; (2) host institute of preference; (3) letter of acceptance from the person at the host institute responsible for the project, including a detailed account of the future research programme, and approval by the Department Head; and (4) a letter from the researcher responsible for the project at the origin institute, including the approval of the Head of Department supporting the candidate's application and explaining his or her expectations careerwise.

The deadline for submission of fellowship applications will be 15 March 1991. Selected recipients will be informed before the end of May 1991, at least for projects to commence in September or October 1991. The Fellowship Committee encourages applications in all areas pertaining to human cancer, with emphasis on clinically related laboratory projects. Selection criteria will be based on the application file submitted. The amount of financial assistance provided will be roughly ECU 30 000 per annum depending to a large extent on the cost of living in the host country. During the period spent in the host institution the fellowship recipients will be allocated a tutor whom he/she will be able to contact for any form of assistance or advice regarding their on-going project and who will in general be responsible to ensure the follow-up of work in progress and liaise with the ESMO Fellowship Committee.

*Eur J Cancer, Vol. 27, No. 2, pp. 215–216, 1991.*  
Printed in Great Britain  
0277-5379/91 \$3.00 + 0.00  
© 1991 Pergamon Press plc

# Letters

## Dacarbazine in Advanced Squamous Cell Carcinoma of the Head and Neck

**José M. Buesa, Roberto Fernández,  
Francisco J. Barón, Isabel Palacio, Juan  
Cueva, Emilio Esteban and José M. Gracia**

ONLY A few drugs have objective activity against advanced squamous cell carcinoma of the head and neck (SCCHN), and more effective agents are needed to improve the prognosis of

Correspondence to J. M. Buesa.

J. M. Buesa, F.J. Barón, I. Palacio, J. Cueva, E. Esteban and J.M. Gracia are at the Servicio de Oncología Médica, Hospital General de Asturias, P.O. Box 243, 33006 Oviedo; and R. Fernandez is at the Servicio de Oncología Médica, Instituto Oncológico, San Sebastián, Spain.

Received 9 Nov. 1990; accepted 16 Nov. 1990.